← Leaderboards
Ricardo C Aguiar
University Of Texas Hlth Science Center
$4,897,608
Attributed
$4,897,608
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $697.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,897,608 · 4
VA$0 · 2
By mechanism
R01$4,649,439 · 3
R21$248,169 · 1
I01$0 · 1
IK6$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Steffan T Nawrocki$3,168,835
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroLinkSignal TransductionGene ExpressionB-LymphocytesMalignant NeoplasmsOncogenicMediatingReportingPathway InteractionsEnzymesGenesCell LineDiagnosisLymphomaBiologyLymphomagenesisS LymphomaLarge Cell Diffuse Non-Hodgkin&AposMouse ModelEpigenetic ProcessPlayMetabolism
Grant awards (30)
Post-Translational Control of TET Function in Lymphoma$0
I01 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Oxidative stress and RNA methylation$387,500
R01 · FY2024 · ES · contact PI
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome$310,000
R01 · FY2024 · GM · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Post-Translational Control of TET Function in Lymphoma$0
I01 · FY2024 · VA · contact PI
Oxidative stress and RNA methylation$387,500
R01 · FY2023 · ES · contact PI
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome$310,000
R01 · FY2023 · GM · contact PI
Post-Translational Control of TET Function in Lymphoma$0
I01 · FY2023 · VA · contact PI
Oxidative stress and RNA methylation$387,500
R01 · FY2022 · ES · contact PI
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome$310,000
R01 · FY2022 · GM · contact PI
Post-Translational Control of TET Function in Lymphoma$0
I01 · FY2022 · VA · contact PI
Oxidative stress and RNA methylation$386,458
R01 · FY2021 · ES · contact PI
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome$308,667
R01 · FY2021 · GM · contact PI
Oxidative stress and RNA methylation$385,000
R01 · FY2020 · ES · contact PI
IRF8 and lymphomagenesis$0
I01 · FY2020 · VA · contact PI
IRF8 and lymphomagenesis$0
I01 · FY2019 · VA · contact PI
IRF8 and lymphomagenesis$0
I01 · FY2018 · VA · contact PI
IRF8 and lymphomagenesis$0
I01 · FY2017 · VA · contact PI
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis$0
I01 · FY2016 · VA · contact PI
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis$0
I01 · FY2015 · VA · contact PI
microRNA-155 and Lymphoma$289,927
R01 · FY2014 · CA · contact PI
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis$0
I01 · FY2014 · VA · contact PI
microRNA-155 and Lymphoma$280,961
R01 · FY2013 · CA · contact PI
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis$0
I01 · FY2013 · VA · contact PI
microRNA-155 and Lymphoma$298,894
R01 · FY2012 · CA · contact PI
microRNA-155 and Lymphoma$298,894
R01 · FY2011 · CA · contact PI
microRNA-155 and Lymphoma$308,138
R01 · FY2010 · CA · contact PI
Phosphodiesterase 4B as a Therapeutic Target in Lymphoma$122,609
R21 · FY2006 · CA · contact PI
Phosphodiesterase 4B as a Therapeutic Target in Lymphoma$125,560
R21 · FY2005 · CA